Nov. 30, 2025 — KA Imaging Technology has announced that its Reveal 35C detector with SpectralDR technology will be featured in two scientific presentations at the Radiological Society of North America (RSNA) annual meeting in Chicago, Ill.

The abstracts, led by independent investigators, explore the potential role of dual-energy chest X-ray in cardiac imaging applications:

Dec.1, 2025 – MannKind Corp. has announced that the U.S. Food and Drug Administration (FDA) has accepted the sNDA seeking approval for FUROSCIX ReadyFlow Autoinjector (SCP-111), developed to deliver a subcutaneous furosemide injection in less than 10 seconds as an investigational alternative to the FDA-approved FUROSCIX (furosemide) On-body Infusor for treatment of edema in adult patients with chronic heart failure (CHF) or chronic kidney disease (CKD). The application has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of July 26, 2026.

Nov. 24, 2025 — InspireMD, Inc., developer of the CGuard Prime carotid stent system for the prevention of stroke, welcomes the recent presentation and publication of CREST-2 data which demonstrated positive clinical outcomes for carotid artery stenting (CAS) for patients with asymptomatic carotid stenosis. CREST-2 data was shown at The Society of Vascular and Interventional Neurology (SVIN) Annual Meeting and the Vascular and Endovascular Issues Techniques and Horizons (VEITH) Symposium on Nov. 21, 2025.

Nov. 19, 2025 — Promising results from a pivotal Phase 3 clinical trial of an investigational heart-attack drug were announced as part of the late-breaking sessions at the American Heart Association Scientific Sessions in New Orleans. The CeleBrate study of zalunfiban (Disaggpro), from CeleCor Therapeutics, met its efficacy and safety endpoints in the treatment of STEMI (heart attack) patients.

Nov. 18, 2025 — RapidAI announced U.S. Food and Drug Administration (FDA) clearance of Aortic Management, part of the Rapid Aortic product, a comprehensive deep clinical AI solution designed to transform the acute assessment and longitudinal management of aortic disease.

Nov. 18, 2025 — Harrison.ai has launched its CE-marked CT Chest solution, a comprehensive AI tool that assists clinicians in detecting 167 radiological features, including those that may be suggestive of life-threatening conditions, tumors, and chronic diseases.

 Nov. 11, 2025 -— Integra LifeSciences Holdings Corp. has announced the FDA 510(k) clearance for use of its CUSA Clarity Ultrasonic Surgical Aspirator System for cardiac surgeries. The recent clearance for specific cardiac indications encompasses the debridement of unwanted tissue in cardiac surgeries, including valve replacement and repair.

Nov. 17, 2025 — GE HealthCare has announced that Cardiovascular Associates of America (CVAUSA) plans to broaden its adoption of GE HealthCare’s FDA-approved cardiac positron emission tomography (PET) radiotracer Flyrcado (flurpiridaz F 18) injection, across approximately 25 sites following a successful pilot at Cardiovascular Medicine in Davenport, Iowa. This planned rollout marks a significant milestone for advancing PET myocardial perfusion imaging (MPI) in community cardiology settings and reflects growing confidence in Flyrcado’s role in shaping the future of cardiac imaging.

Nov. 12, 2025 — The Association of Black Cardiologists (ABC) has released new findings from a national survey exposing a widespread gap in awareness regarding cholesterol and cardiovascular health. These insights reinforce the urgency of the organization’s “Every Heart Counts: ABC Cardiology Deserts Campaign” — a nationwide initiative addressing persistent disparities in access to heart health education and care in under-resourced regions across the country.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now